Bli medlem
Bli medlem

Du är här


Prothena Announces Appointment of Chief Regulatory Officer

ointment of Chief Regulatory Officer

DUBLIN, Ireland, 2016-12-15 22:05 CET (GLOBE NEWSWIRE) --
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology
company focused on the discovery, development and commercialization of novel
protein immunotherapies, announced today the appointment of Carol D. Karp as
Chief Regulatory Officer. Ms. Karp will lead Prothena’s Quality, Regulatory and
Safety organizations.

This new position adds important expertise in line with Prothena’s continued
growth as a late-stage clinical biotechnology company with integrated research,
development and commercial capabilities.

"Carol is a highly regarded leader who has successfully led global regulatory,
quality and safety activities across multiple therapeutic areas and all stages
of product development,” said Gene Kinney, PhD, President and Chief Executive
Officer of Prothena. “She joins Prothena as we are making steady advances
across our pipeline and continue to prepare our commercial infrastructure in
advance of key clinical data. We are delighted to have someone with Carol’s
expertise join our team to lead these key strategic activities.”

Prior to joining Prothena, Ms. Karp was an independent regulatory consultant
with an extensive and successful track record of leading global registration
activities for innovative new products in the biotechnology and pharmaceutical
sectors. Ms. Karp previously held executive leadership positions as Senior Vice
President of Regulatory Affairs and Compliance at Esperion Therapeutics, and
Vice President and Head of Global Regulatory Affairs, Pharmacovigilance & Risk
Management at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company,
where she led global regulatory affairs, regulatory operations and CMC
regulatory for a portfolio of neurodegenerative product candidates. Prior to
Janssen, Ms. Karp was Senior Vice President, Regulatory Affairs, Quality
Assurance and Drug Safety at CV Therapeutics, which was acquired by Gilead
Sciences. Ms. Karp also held senior regulatory and scientific affairs positions
at PowderJect, VIVUS, Cygnus and Janssen Pharmaceutica.

Ms. Karp is a member of the Board of Trustees at the University of Rochester,
and an expert advisor and member of the selection and review committees for the
Stanford University School of Medicine’s SPARK translational research program.
Ms. Karp earned her BA in biology from the University of Rochester.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep
scientific understanding built over decades of research in protein misfolding
and cell adhesion — the root causes of many serious or currently untreatable
amyloid and inflammatory diseases — Prothena is establishing a fully integrated
research, development and commercial focus and has advanced several drug
candidates into clinical studies while pursuing discovery of additional novel
therapies. Our pipeline of antibody-based product candidates targets a number
of potential indications including AL amyloidosis (NEOD001), Parkinson's
disease and other related synucleinopathies (PRX002), inflammatory diseases,
including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis
(PRX004). For more information, please visit the company's website at


Investors: Tran Nguyen, CFO

Media: Ellen Rose

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.